This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income

AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.

The Motley Fool • 12 hours ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026.

PRNewsWire • 12 hours ago

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • 10 hours ago

Here's Why AbbVie (ABBV) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • 10 hours ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its Illinois campus, expanding its domestic production capacity for its neuroscience and obesity medicines.

Reuters • Feb 23, 2026

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Investment marks continued progress against AbbVie's $100 billion commitment to U.S. research and development (R&D) and capital investments, including manufacturing, over the next decade Two new facilities will be built to add advanced manufacturing capabilities to support the production of next-generation neuroscience and obesity medicines Construction will begin in spring 2026, with the site fully operational in 2029 NORTH CHICAGO, Ill., Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus.

PRNewsWire • Feb 23, 2026

Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs

JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.

Zacks Investment Research • Feb 23, 2026

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the potential of time off treatment, marking a meaningful advance in long-term disease management NORTH CHICAGO, Ill., Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL).

PRNewsWire • Feb 20, 2026

Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?

AbbVie ABBV announced encouraging fourth-quarter and full-year 2025 results earlier this month that beat expectations. A major portion of the company's top-line growth came from its newer immunology medicines, Rinvoq and Skyrizi, which not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie's key growth drivers.

Zacks Investment Research • Feb 20, 2026

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.

PRNewsWire • Feb 19, 2026